[Update on heart failure]

J Wintrich1, I Kindermann2, M Böhm2

  • 1Klinik für Innere Medizin III - Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrbergerstraße, 66421, Homburg/Saar, Deutschland. Jan.Wintrich@uks.eu.

Herz
|June 6, 2018
PubMed

Insights

Heart failure management is crucial due to rising prevalence. Recent advances, including neprilysin inhibition, improve outcomes, but guideline-conform treatment remains vital for patients with heart failure.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Pharmacology

Background:

  • Heart failure is a leading global disease, with increasing incidence due to aging populations.
  • It is the most frequent diagnosis in hospitalized patients in Germany, despite recent mortality reductions.
  • High mortality and morbidity rates necessitate guideline-conform treatment.

Purpose of the Study:

  • To review current scientific knowledge on heart failure (2017-2018) based on European Society of Cardiology guidelines.
  • To present new findings on heart failure with mid-range ejection fraction limitations.
  • To discuss innovative diagnostic and therapeutic strategies, pharmacological developments, and comorbidity management.

Main Methods:

  • Literature review of scientific knowledge from 2017-2018.
  • Focus on European Society of Cardiology guidelines for heart failure management.
  • Synthesis of information on diagnosis, therapy, and comorbidities.

Main Results:

  • Highlights recent advancements in heart failure treatment, including neprilysin inhibition.
  • Introduces new aspects of heart failure with mid-range ejection fraction.
  • Discusses innovative diagnostic tools and therapeutic approaches.

Conclusions:

  • Guideline-conform treatment is essential for managing heart failure.
  • New pharmacological options offer improved outcomes but do not eliminate risks.
  • Comprehensive management addressing comorbidities is key for heart failure patients.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
987
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
937
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
385
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
352